Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

40.01USD
16 Feb 2018
Change (% chg)

$-0.61 (-1.50%)
Prev Close
$40.62
Open
$40.88
Day's High
$42.08
Day's Low
$39.50
Volume
192,042
Avg. Vol
167,132
52-wk High
$44.96
52-wk Low
$13.50

Latest Key Developments (Source: Significant Developments)

Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
Thursday, 4 Jan 2018 07:03pm EST 

Jan 4 (Reuters) - Crispr Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $22.75PER SHARE.  Full Article

Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​
Wednesday, 3 Jan 2018 06:15am EST 

Jan 3 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - ‍COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON SHARES​.  Full Article

Crispr Therapeutics Announces Appointment Of Dr. Rodger Novak As Chairman Of The Board
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. RODGER NOVAK AS CHAIRMAN OF THE BOARD.CRISPR THERAPEUTICS AG - ‍RODGER NOVAK WILL SUCCEED TONY COLES​.CRISPR THERAPEUTICS AG - ‍TONY COLES WILL REMAIN A SENIOR ADVISOR TO CRISPR THERAPEUTICS​.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS SUBMITS FIRST CLINICAL TRIAL APPLICATION FOR A CRISPR GENE-EDITED THERAPY, CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - ANNOUNCED SUBMISSION OF A CLINICAL TRIAL APPLICATION FOR CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - PHASE 1/2 TRIAL OF CTX001 IS EXPECTED TO BEGIN IN EUROPE IN 2018.CRISPR THERAPEUTICS AG - CO ALSO PLANS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 TO TREAT SICKLE CELL DISEASE WITH U.S. FDA IN 2018.  Full Article

CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs
Monday, 13 Nov 2017 05:00am EST 

Nov 13 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs.‍Under terms, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications​.‍In exchange, CureVac will receive an upfront payment and research funding ​.CRISPR Therapeutics-‍CureVac to also be eligible to receive development, commercial milestones, royalties on commercialized products from collaboration​.  Full Article

Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:33pm EST 

Nov 9 (Reuters) - Crispr Therapeutics AG :Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​.  Full Article

CRISPR Therapeutics announces third quarter results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics announces third quarter 2017 financial results and provides business update.CRISPR Therapeutics ag qtrly net ‍loss per share attributable to common shareholders​ of $0.62.  Full Article

CRISPR Therapeutics promotes Samarth Kulkarni to CEO
Monday, 2 Oct 2017 07:30am EDT 

Oct 2 (Reuters) - Crispr Therapeutics Ag :CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer.CRISPR Therapeutics - ‍rodger Novak, co-founder and current CEO, is stepping down from his current role for personal reasons​.CRISPR Therapeutics - Rodger Novak to continue to serve as member of co's board and as an officer of its Swiss parent company, CRISPR AG​.  Full Article

Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​
Thursday, 10 Aug 2017 04:35pm EDT 

Aug 10 (Reuters) - Crispr Therapeutics Ag :Crispr Therapeutics announces second quarter 2017 financial results and provides business update.Crispr Therapeutics Ag - ‍as of June 30, 2017, Crispr Therapeutics had $272.3 million in cash as compared to $315.5 million in cash as of December 31, 2016​.Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​.Crispr Therapeutics Ag - ‍lead hemoglobinopathies program remains on track to file CTA by year-end 2017, and begin clinical trials in 2018​.Crispr Therapeutics Ag - ‍remains on track to file a clinical trial application (CTA) in Europe by year-end 2017 for beta-thalassemia​.  Full Article